Industry News
TASTE trial challenge current practice of blood clot aspiration after heart attack
Sep 03, 2013
Aspiration of the blood clot or "thrombus" that causes a heart attack before re-opening a patient's artery with a balloon catheter does not improve survival compared to performing balloon dilation and stenting alone according to the results of the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial... Read More
Scientists discover novel functions of platelets
Sep 03, 2013
A new finding could lead to novel treatments to reduce bleeding in trauma and severe infections. The research, from Oklahoma Medical Research Foundation scientists Lijun Xia, M.D., Ph.D., Jianxin Fu, M.D., Ph.D., and Brett Herzog, Ph.D., appears in the most recent issue of the journal Nature. One way the immune system keeps a body healthy is through immune surveillance... Read More
Collagen clue reveals new drug target for untreatable form of lung cancer
Sep 03, 2013
Collagen, the stuff of ligaments and skin, and the most abundant protein in the human body, has an extraordinary role in triggering chemical signals that help protect the body from cancer, a new study reveals. Scientists at The Institute of Cancer Research, London, have uncovered a series of chemical signals sent out by collagen that appear to protect against cancer's growth... Read More
Researchers develop specific tests to identify cancer biomarkers in dermatomyositis
Sep 03, 2013
Researchers from major universities in the U.S. have developed specific tests to identify cancer biomarkers in patients with dermatomyositis - a systemic inflammatory disease associated with increased risk of malignancy... Read More
Discovery of genetic mutation in castration-resistant prostate cancer could lead to development of biomarkers and new targeted therapies
Sep 02, 2013
The mutation occurs in the androgen-synthesizing enzyme 3βHSD1 in castration-resistant prostate cancer (CRPC), according to research published online in Cell. This mutation enables the tumor to make its own supply of androgens, a hormone that fuels the growth of the prostate cancer. Prostate cancer requires a constant supply of androgens in order to sustain itself... Read More
Highlights from the XV International Congress of Immunology, Milan
Sep 02, 2013
New perspectives against transplant rejection New scientific results that could one day allow transplanted patients to avoid side effects caused by immunosuppressive therapy were presented at the International Congress of Immunology in Milan... Read More
Susceptibility to prostate cancer increased by mutations in a gene that impacts immune function
Sep 02, 2013
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer... Read More
Discovery of genetic mutation in castration-resistant prostate cancer could lead to development of biomarkers and new targeted therapies
Sep 02, 2013
The mutation occurs in the androgen-synthesizing enzyme 3βHSD1 in castration-resistant prostate cancer (CRPC), according to research published online in Cell. This mutation enables the tumor to make its own supply of androgens, a hormone that fuels the growth of the prostate cancer. Prostate cancer requires a constant supply of androgens in order to sustain itself... Read More
New strategy against high-risk leukemia
Sep 02, 2013
St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective method of killing tumor cells. The findings appear in the journal Blood... Read More
Breast cancer prognosis predicted by protein
Sep 02, 2013
Researchers have identified a protein that they believe may help predict breast cancer prognosis, potentially relieving thousands of women at low risk from having to undergo painful, oft-debilitating therapies, while insuring the most successful treatments for those at high risk. The research was published ahead of print in the journal Molecular and Cellular Biology... Read More
Previous Page Next Page